Improved Antitumor Activity of a Therapeutic Melanoma Vaccine through the Use of the Dual COX-2/5-LO Inhibitor Licofelone.

Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol (2009) 25.96

The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 24.94

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol (2010) 17.13

Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol (2012) 12.19

Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol (2007) 9.37

Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol (2008) 9.25

Cyclooxygenase in biology and disease. FASEB J (1998) 7.17

Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol (2012) 5.23

Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res (2007) 4.69

Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J Exp Med (2003) 4.44

Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res (2007) 4.39

Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol (2010) 4.06

Regulation of immune responses by prostaglandin E2. J Immunol (2012) 3.93

Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. Immunity (2010) 3.88

GM-CSF Mouse Bone Marrow Cultures Comprise a Heterogeneous Population of CD11c(+)MHCII(+) Macrophages and Dendritic Cells. Immunity (2015) 3.87

Suppressors of cytokine signaling and immunity. Nat Immunol (2003) 3.68

Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. Eur J Immunol (2010) 3.18

History of myeloid-derived suppressor cells. Nat Rev Cancer (2013) 3.14

Differentiation of Tr1 cells by immature dendritic cells requires IL-10 but not CD25+CD4+ Tr cells. Blood (2004) 2.76

Dendritic cells from mouse bone marrow: in vitro differentiation using low doses of recombinant granulocyte-macrophage colony-stimulating factor. J Immunol Methods (1992) 2.66

Invariant NKT cells reduce the immunosuppressive activity of influenza A virus-induced myeloid-derived suppressor cells in mice and humans. J Clin Invest (2008) 2.46

Mechanism of T cell tolerance induced by myeloid-derived suppressor cells. J Immunol (2010) 2.20

Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells. Blood (2011) 2.05

Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression. Semin Cancer Biol (2012) 2.01

PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. Cancer Res (2011) 1.87

Inflammasomes in carcinogenesis and anticancer immune responses. Nat Immunol (2012) 1.85

Subsets, expansion and activation of myeloid-derived suppressor cells. Med Microbiol Immunol (2010) 1.67

Specificity of expression and effects of eicosanoid mediators in normal physiology and human diseases. FASEB J (1995) 1.64

Dual inhibition of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) as a new strategy to provide safer non-steroidal anti-inflammatory drugs. Eur J Med Chem (2003) 1.60

Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T cells. Clin Cancer Res (2013) 1.43

COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function. BMC Cancer (2010) 1.43

Eicosanoid storm in infection and inflammation. Nat Rev Immunol (2015) 1.35

Mechanism of adjuvant activity of cationic liposome: phosphorylation of a MAP kinase, ERK and induction of chemokines. Mol Immunol (2007) 1.24

Efficient synthesis of alpha-galactosyl ceramide analogues using glycosyl iodide donors. Org Lett (2005) 1.22

Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation. Eur J Immunol (2008) 1.16

Myeloid cell population dynamics in healthy and tumor-bearing mice. Int Immunopharmacol (2011) 1.07

Anti-IL-6 receptor mAb eliminates myeloid-derived suppressor cells and inhibits tumor growth by enhancing T-cell responses. Eur J Immunol (2012) 1.04

Chemoprevention of colon and small intestinal tumorigenesis in APC(Min/+) mice by licofelone, a novel dual 5-LOX/COX inhibitor: potential implications for human colon cancer prevention. Cancer Prev Res (Phila) (2011) 1.04

Reactive oxygen species play a central role in the activity of cationic liposome based cancer vaccine. J Control Release (2008) 1.03

Chemopreventive agents induce oxidative stress in cancer cells leading to COX-2 overexpression and COX-2-independent cell death. Carcinogenesis (2008) 1.01

Licofelone, a dual COX/5-LOX inhibitor, induces apoptosis in HCA-7 colon cancer cells through the mitochondrial pathway independently from its ability to affect the arachidonic acid cascade. Carcinogenesis (2007) 1.00

Immunostimulation of dendritic cells by cationic liposomes. Mol Membr Biol (2006) 0.96

Activation of the NLRP3 inflammasome is not a feature of all particulate vaccine adjuvants. Immunol Cell Biol (2014) 0.94

Myeloid-derived suppressor cells are associated with disease progression and decreased overall survival in advanced-stage melanoma patients. Cancer Immunol Immunother (2013) 0.94

The molecular mechanism of the inhibition by licofelone of the biosynthesis of 5-lipoxygenase products. Br J Pharmacol (2007) 0.88

Anticancer effects of licofelone (ML-3000) in prostate cancer cells. Anticancer Res (2007) 0.85

Particulate delivery systems for vaccines: what can we expect? J Pharm Pharmacol (2006) 0.84

5-lipoxygenase: underappreciated role of a pro-inflammatory enzyme in tumorigenesis. Front Pharmacol (2010) 0.83

Absence of LTB4/BLT1 axis facilitates generation of mouse GM-CSF-induced long-lasting antitumor immunologic memory by enhancing innate and adaptive immune systems. Blood (2012) 0.82

Chemopreventive efficacy and mechanism of licofelone in a mouse lung tumor model via aspiration. Cancer Prev Res (Phila) (2011) 0.81

Differential response of myeloid-derived suppressor cells to the nonsteroidal anti-inflammatory agent indomethacin in tumor-associated and tumor-free microenvironments. J Immunol (2015) 0.79

Simultaneous targeting of 5-LOX-COX and ODC block NNK-induced lung adenoma progression to adenocarcinoma in A/J mice. Am J Cancer Res (2016) 0.79

Synthetic TRP2 long-peptide and α-galactosylceramide formulated into cationic liposomes elicit CD8(+) T-cell responses and prevent tumour progression. Vaccine (2015) 0.78

New strategies for melanoma immunotherapy: How to overcome immunosuppression in the tumor microenvironment. Oncoimmunology (2012) 0.76